Day: October 24, 2020

Fura Provides Update on Going Private Transaction

TORONTO, Oct. 24, 2020 (GLOBE NEWSWIRE) — Fura Gems Inc. (“Fura” or the “Company”) (TSXV: FURA, OTC: FUGMF and FRA: BJ43) is pleased to provide an update on its previously announced going private transaction (the “Transaction”). The parties are working diligently to complete the remaining legal formalities in relation to the Transaction, which is now expected to close on or about October 28, 2020, subject to the satisfaction or waiver of certain conditions.The Transaction is more fully described in the management information circular (the “Circular”) which was mailed to shareholders of record as of September 1, 2020. The Circular is available under Fura’s profile on SEDAR at www.sedar.com.About Fura Gems Inc.Fura Gems Inc. is a gemstone mining and marketing company which is engaged in the mining, exploration and acquisition of gemstone...

Continue reading

Festi hf.: Endurkaup vika 43

Í 43. viku 2020 keypti Festi alls 750.000 hluti eins og hér segir:Um er að ræða tilkynningu um kaup Festi á eigin bréfum í samræmi við endurkaupaáætlun sem var tilkynnt um 4. október 2020 í tilkynningu til Nasdaq OMX Iceland. Áætlað er að kaupa á hámarki 4.000.000 eigin hluti í félaginu eða sem samsvarar 1,2% af útgefnu hlutafé, þó þannig að fjárhæð endurkaupanna verði aldrei meiri en 600 milljónum króna að kaupverði.Fyrir kaupin átti Festi 5.645.407 hluti eða 1,70% af útgefnu hlutafé. Festi á í dag 7.795.407 hluti sem samsvarar 2,34% af hlutafé félagsins.Framkvæmd endurkaupaáætlunarinnar er í samræmi við VIII. kafla laga um hlutafélög nr. 2/1995 og viðauka II við reglugerð um innherjaupplýsingar og markaðssvik nr. 630/2005.Nánari upplýsingar veitir Eggert Þór Kristófersson, forstjóri Festi hf., (eggert@festi.is) og Magnús Kr. Ingason,...

Continue reading

Festi hf.: Buy-back programme week 43

In week 43 Festi purchased in total 750.000 shares:This announcement of purchase of own shares is in accordance with the buy-back programme announced 4 October 2020 to Nasdaq OMX Iceland. The programme envisages the buy-back of a total of 4.000.000 own shares or 1.2% of the issued shares, with the cap of 600 million ISK purchase price.Before the purchase Festi held 5.645.407 shares or 1.70% of issued shares. Festi today holds 7.795.407 shares or 2.34% of issued shares.The execution the buy-back programme is in accordance with Chapter VIII of the Company Act No 2/1995 and annex II to the Regulation on insider information and market abuse No 630/2005.For further information contact Eggert Þór Kristófersson, CEO of Festi hf., (eggert@festi.is) and Magnús Kr. Ingason, CFO of Festi hf. (mki@festi.is).

Continue reading

Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium

Preliminary Clinical Activity and Safety Profile Support Advancing to Dose Expansion in Multiple Tumor Types Recommended Phase 2 Dose Determination OngoingPreclinical Combination Data for Lead Drug Candidate Repotrectinib in both KRAS Tumor Models and Pediatric Neuroblastoma Tumor Models Also PresentedConference Call Scheduled for 11:00 a.m. Eastern TimeSAN DIEGO, Oct. 24, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase 1 dose finding portion of its SHIELD-1 study of drug candidate, TPX-0022, a potent inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R. The initial data highlighted preliminary clinical activity, including...

Continue reading

Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

Plenary Presentation at EORTC-NCI-AACR 32ndSymposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and Early Evidence of Clinical Activity in RASmutColorectal CancersCompany Also Announces New Clinical Collaboration with AstraZeneca to Study RMC-4630 in Combination with an Emerging AstraZeneca Asset Targeting KRASG12CREDWOOD CITY, Calif., Oct. 24, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today reported interim data from the company’s ongoing Phase 1b/2 clinical trial (RMC-4630-02) evaluating the combination of RMC-4630 and cobimetinib (Cotellic®) in an oral presentation by Johanna C. Bendell,...

Continue reading

Private Placement Markets – Insurance Market to Expand in January of 2021 to Include Life Settlement

The Life Settlement Industry recorded about $3.8 Billion in 2018 transactions. According to a study by The Deal, the 2019 transactions are believed to be about 28% greater than in 2018. A life settlement refers to the sale of an existing insurance policy to a third-party for a one-time cash payment. The one-time cash payment is more than the “surrender value”, but is generally far less than the actual death benefit. After the sale, the purchaser of the life insurance policy becomes the policy’s “Beneficiary”, and assumes payment of its premiums. By doing so, he / she / it receives the death benefit when the insured party passes away. Steve Muehler stated that “the volume of transactions in life settlement policies has been increasing dramatically as life settlements become more known, and this positive surge seems to continue. The face...

Continue reading

Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium

First and only chemoprotective therapy in clinical development that utilizes a biomarker strategy designed to protect patients with p53-mutated cancers from chemotherapy-induced toxicities and side effectsTreatment with ALRN-6924 prior to topotecan administration resulted in a protective effect against severe chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC)Robust and clinically meaningful protection against toxicities observed with 0.3 mg/kg dose of ALRN-6924Aileron to host conference call and webcast on Monday, October 26, 2020 at 8:30 a.m. ET to discuss the data and its clinical development strategy to expand chemoprotection to multiple p53-mutated cancers and chemotherapiesWATERTOWN, Mass., Oct. 24, 2020 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN) today announced...

Continue reading

CF Energy Responds to Dissident Misrepresentation Regarding Gas Price Policy

TORONTO, Oct. 23, 2020 (GLOBE NEWSWIRE) — In connection with the annual meeting of shareholders of CF Energy Corp. (TSX-V: CFY) (“CF Energy” or the “Company”) to be held on October 29, 2020 (the “Meeting”), the dissident shareholder 11882716 Canada Inc. (the “Nominating Shareholder”) has filed a dissident proxy circular dated October 14, 2020 (the “Dissident Circular”) and issued a press release dated October 16, 2020 (the “Dissident Press Release”).In the Dissident Press Release, the Nominating Shareholder and Dissident Nominees attempt to further mislead shareholders by alleging that the Company has not complied with the PRC Central Government’s natural gas price reduction policies. This allegation is false, and demonstrates that the Nominating Shareholder and Dissident Nominees do not understand the regulation of pricing in the...

Continue reading

LOMIKO CLOSES OVERSUBSCRIBED FINANCING OF $750,000

Vancouver, B.C., Oct. 23, 2020 (GLOBE NEWSWIRE) — Lomiko Metals Inc. (“Lomiko”) (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) announces it has received subscriptions and closed it private placement financing, and raised $750,000 through the sale of 15,000,000 units at the price of $0.05 per unit.  Each unit consisting of one common share and warrant exercisable for two years at $0.10 from the closing date. Proceeds will be for working capital.  The securities will be issued having a four-month plus one day hold period.  The issuance of the securities is subject to the final approval of the TSX.A director of the Company participated as to an aggregate of 3,000,000 Units.  The participation in the private placement by the director of the Company may be considered a “related party transaction” (the “Related Party”) as...

Continue reading